The White House announced last Friday that President Biden (D) had signed into law the bipartisan Medical Marijuana and Cannabidiol Research Expansion Act (HR 8454). The signing was historic; it marked the first time a president has signed a standalone marijuana reform bill into law. Some marijuana reform measures have been passed before, but only as part of much broader appropriations bills.

[image:1 align:right caption:true]With lead sponsors Rep. Earl Blumenauer (D-OR), head of the Congressional Cannabis Caucus, and Sen. Dianne Feinstein (D-CA) in their respective chambers, the bill passed by unanimous consent, first in the House and then late last month in the Senate.

The aim of the bill is to facilitate research on marijuana and its potential health benefits. The bill will accomplish this by streamlining the application process for scientific marijuana studies and removing existing barriers for researchers that frequently slow the research process. It will broaden marijuana research by allowing both private companies and research universities to seek DEA licenses to grow their own marijuana for research purposes.

The bill calls on the Department of Health and Human Services (HHS) to study potential therapeutic benefits of the plant, which could have an impact on a rescheduling review Biden ordered in October. But that HHS mandate also includes language requiring research on how marijuana may affect one's ability to drive and the impact of its use on teenage brains.

"Today marks a monumental step in remedying our federal cannabis laws," said Blumenauer and Cannabis Caucus co-chairs Dave Joyce (R-OH), Barbara Lee (D-CA), and Brian Mast R-FL) in a statement after the signing."We celebrate the enactment of this critical and long-overdue legislation, and we know there is much more to do to remedy the ongoing harms of the failed war on drugs."

Among the bill's cosponsors in the Senate was Sen. Charles Grassley (R-IA). Both he and Sen. Feinstein have been among the Senate's most ardent drug warriors going well back into the last century. While this bill is fairly conservative -- it does not directly address rescheduling marijuana or take up the question of access to financial services, let alone legalization -- that both Feinstein and Grassley back it is a sign of how far we've come.

"I've heard directly from Iowans who are desperately in search of treatment options for conditions like child epilepsy," Grassley said in a statement "Unfortunately, many families have resorted to using untested, unregulated derivatives from the marijuana plant as a last resort to treat these conditions. Since 2015, I've pushed to expand medical research into marijuana derivatives such as cannabidiol to better understand their benefits and potential harms. This research is a critical step toward ensuring safe and effective therapies are also consistently regulated like any other prescription drug."

"There is substantial evidence that marijuana-derived medications can and are providing major health benefits," Sen. Feinstein said in a statement. "Our bill will make it easier to study how these medications can treat various conditions, resulting in more patients being able to easily access safe medications. We know that cannabidiol-derived medications can be effective for conditions like epilepsy. This bill will help refine current medical CBD practices and develop important new applications. After years of negotiation, I'm delighted that we're finally enacting this bill that will result in critical research that could help millions," she added.

Now is the time to press for more reform, said Blumenauer.

"Finally, the dam is starting to break," he said in a separate statement. "The passage of my Medical Marijuana and Cannabidiol Research Expansion Act in the House and Senate represents a historic breakthrough in addressing the federal government's failed and misguided prohibition of cannabis."

"As we have seen in state after state, the public is tired of waiting for the federal government to catch up. Nearly half of our nation's population now live in states where adult-use of cannabis is legal. For far too long, Congress has stood in the way of science and progress, creating barriers for researchers attempting to study cannabis and its benefits. At a time when more than 155 million Americans reside where adult-use of cannabis is legal at the state or local level and there are four million registered medical marijuana users with many more likely to self-medicate, it is essential that we are able to fully study the impacts of cannabis use."

"The passage of this legislation coming just weeks after the change in President Biden's posture towards cannabis is extraordinarily significant. We must capitalize on this momentum to move subsequent common-sense House-passed bills like the SAFE Banking Act, which finally allows state-legal dispensaries to access banking services and reduce their risk of violent robberies."

There are, indeed, moves afoot to get the SAFE Banking Act passed during the remainder of the lame duck session, but time is running short and the clock is ticking.